

Company Number: 268722

**Cloughjordan Pharmacy Limited**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 30 June 2025**

# Cloughjordan Pharmacy Limited

## CONTENTS

	<b>Page</b>
Directors' Responsibilities Statement	3
Balance Sheet	4
Reconciliation of Shareholders' Funds	5
Notes to the Financial Statements	6 - 10

# Cloughjordan Pharmacy Limited

## DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 June 2025

The directors made the following statement in respect of the unaudited financial statements:

### "General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet, the Reconciliation of Shareholders' Funds and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to Duggan & Power, (Chartered Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 30 June 2025."

### Signed on behalf of the board

**Peter Fox**  
Director

**1 December 2025**

**Patricia Fox**  
Director

**1 December 2025**

# Cloughjordan Pharmacy Limited

## BALANCE SHEET

as at 30 June 2025

	Notes	2025 €	2024 €
<b>Fixed Assets</b>			
Tangible assets	7	39,951	66,566
<b>Current Assets</b>			
Stocks	8	90,212	100,151
Debtors	9	131,083	106,398
Cash and cash equivalents		20,180	5,237
		241,475	211,786
<b>Creditors: amounts falling due within one year</b>	10	(85,049)	(82,505)
<b>Net Current Assets</b>		156,426	129,281
<b>Total Assets less Current Liabilities</b>		196,377	195,847
<b>Creditors:</b>			
amounts falling due after more than one year	11	(28,943)	(44,528)
<b>Net Assets</b>		167,434	151,319
<b>Capital and Reserves</b>			
Called up share capital presented as equity		127	127
Retained earnings		167,307	151,192
<b>Equity attributable to owners of the company</b>		167,434	151,319

We as Directors of Cloughjordan Pharmacy Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

**Approved by the board on 1 December 2025 and signed on its behalf by:**

**Peter Fox**  
Director

**Patricia Fox**  
Director

# Cloughjordan Pharmacy Limited

## RECONCILIATION OF SHAREHOLDERS' FUNDS

as at 30 June 2025

	Called up share capital €	Retained earnings €	Total €
<b>At 1 July 2023</b>	127	192,048	192,175
Loss for the financial year	-	(40,856)	(40,856)
<b>At 30 June 2024</b>	127	151,192	151,319
Profit for the financial year	-	16,115	16,115
<b>At 30 June 2025</b>	<b>127</b>	<b>167,307</b>	<b>167,434</b>

# Cloughjordan Pharmacy Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

### 1. General Information

Cloughjordan Pharmacy Limited is a company limited by shares incorporated in Ireland. C/O Duggan & Power, Emmet Square, Birr, Co. Offaly is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### Statement of compliance

The financial statements of the company for the year ended 30 June 2025 have been prepared on the going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102).

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

#### Cash flow statement

The company has availed of the exemption in FRS 102 from the requirement to prepare a Cash Flow Statement because it is classified as a small company.

#### Turnover

Turnover represents the total invoice value, excluding value added tax, of sales made during the year.

#### Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	10% to 35% Straight line
Motor vehicles	-	20% Reducing Balance

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

#### Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

#### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

# Cloughjordan Pharmacy Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

### Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

### Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

### Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

### Ordinary share capital

The ordinary share capital of the company is presented as equity.

<b>3. Operating profit/(loss)</b>	<b>2025</b>	2024
	€	€
<b>Operating profit/(loss) is stated after charging:</b>		
Depreciation of tangible assets	<b>28,777</b>	26,771
	<u>          </u>	<u>          </u>
<b>4. Interest payable and similar expenses</b>	<b>2025</b>	2024
	€	€
Interest	<b>2,483</b>	3,326
	<u>          </u>	<u>          </u>

### 5. Employees

The average monthly number of employees, including directors, during the financial year was 9, (2024 - 11).

	<b>2025</b>	2024
	Number	Number
Employees	<b>9</b>	9
Director	<b>2</b>	2
	<u>          </u>	<u>          </u>
	<b>11</b>	11
	<u>          </u>	<u>          </u>

## Cloughjordan Pharmacy Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

### 6. Tax on profit/(loss)

	2025 €	2024 €
<b>Analysis of charge in the financial year</b>		
<b>Current tax:</b>		
Corporation tax	-	-

### (b) Factors affecting tax charge for the financial year

The tax assessed for the financial year differs from the standard rate of corporation tax in the Republic of Ireland. The differences are explained below:

	2025 €	2024 €
Profit/(loss) taxable at 0.00%	<u>16,115</u>	<u>(40,856)</u>

No charge to tax arises due to tax losses incurred.

### 7. Tangible assets

	Fixtures, fittings and equipment €	Motor vehicles €	Total €
<b>Cost</b>			
At 1 July 2024	364,736	15,323	380,059
Additions	2,162	-	2,162
At 30 June 2025	<u>366,898</u>	<u>15,323</u>	<u>382,221</u>
<b>Depreciation</b>			
At 1 July 2024	303,534	9,959	313,493
Charge for the financial year	26,862	1,915	28,777
At 30 June 2025	<u>330,396</u>	<u>11,874</u>	<u>342,270</u>
<b>Net book value</b>			
At 30 June 2025	<u>36,502</u>	<u>3,449</u>	<u>39,951</u>
At 30 June 2024	<u>61,202</u>	<u>5,364</u>	<u>66,566</u>

### 8. Stocks

	2025 €	2024 €
Finished goods and goods for resale	<u>90,212</u>	<u>100,151</u>

The replacement cost of stock did not differ significantly from the figures shown.

## Cloughjordan Pharmacy Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

<b>9. Debtors</b>	<b>2025</b>	<b>2024</b>
	€	€
Trade debtors	<b>68,501</b>	52,259
Rx Loan Value	<b>93</b>	7
Other debtors	<b>860</b>	-
Directors' current accounts	<b>3,264</b>	3,264
Taxation and social welfare	<b>51,845</b>	44,348
Prepayments	<b>6,520</b>	6,520
	<b>131,083</b>	106,398
	<u><u>          </u></u>	<u><u>          </u></u>
<b>10. Creditors</b>	<b>2025</b>	<b>2024</b>
<b>Amounts falling due within one year</b>	€	€
Amounts owed to credit institutions	<b>18,060</b>	18,060
Trade creditors	<b>47,109</b>	35,602
Taxation and social welfare	<b>6,975</b>	21,167
Other creditors	<b>6,585</b>	3,476
Pension accrual	<b>2,120</b>	-
Accruals	<b>4,200</b>	4,200
	<b>85,049</b>	82,505
	<u><u>          </u></u>	<u><u>          </u></u>
<b>11. Creditors</b>	<b>2025</b>	<b>2024</b>
<b>Amounts falling due after more than one year</b>	€	€
Bank loan	<b>28,943</b>	44,528
	<u><u>          </u></u>	<u><u>          </u></u>
<b>Loans</b>		
Repayable in one year or less, or on demand	<b>18,060</b>	18,060
Repayable between one and two years	<b>18,060</b>	18,060
Repayable between two and five years	<b>10,883</b>	26,468
	<b>47,003</b>	62,588
	<u><u>          </u></u>	<u><u>          </u></u>
<b>12. Income Statement</b>		
	<b>2025</b>	<b>2024</b>
	€	€
At 1 July 2024	<b>151,192</b>	192,048
Profit/(loss) for the financial year	<b>16,115</b>	(40,856)
	<u><u>          </u></u>	<u><u>          </u></u>
At 30 June 2025	<b>167,307</b>	151,192
	<u><u>          </u></u>	<u><u>          </u></u>
<b>13. Capital commitments</b>		

The company had no material capital commitments at the financial year-ended 30 June 2025.

## Cloughjordan Pharmacy Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

<b>14. Directors' remuneration</b>	<b>2025</b>	2024
	€	€
Remuneration	<b>66,000</b>	62,000
Pension contributions	<b>50,000</b>	75,000
	<u><b>116,000</b></u>	<u>137,000</u>

## 15. Related party transactions

The following material related party transactions took place between the company and its Directors during the period:

- Directors Remuneration as set out in note 13 to the accounts.

Transactions with group companies include ...

The following material related party transactions took place between the company and its Directors during the period:

- Directors Remuneration as set out in note 13 to the accounts.

## 16. Parent and ultimate parent company

The company regards Peter Fox Pharmacy Holdings Ltd as its parent company.

The ultimate parent company is Peter Fox Pharmacy Holdings Limited which owns 95% of the issued share capital.

Peter Fox Pharmacy Holdings Ltd is regarded as both the controlling party and the ultimate controlling party.

## 17. Post-Balance Sheet Events

There have been no significant events affecting the company since the year end.

## 18. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 1 December 2025.